FutureChem, a company specializing in radiopharmaceuticals, announced on the 22nd that it has signed an exclusive license and supply agreement with Hanoi Investigation Center (HIC) in Vietnam for 'ProstaView,' a radiopharmaceutical for the diagnosis of prostate cancer.


FutureChem Signs Exclusive Supply Agreement with Vietnam's HIC for Prostate Cancer Diagnostic Drug View original image

Under the agreement, FutureChem will receive an upfront payment of USD 100,000 and will also be entitled to a running royalty of 15% of ProstaView's net sales in Vietnam. The company will exclusively supply dedicated cassettes, precursors, and reagent kits used consistently during the local production process as a package. According to FutureChem, in addition to the initial payment and sales-based royalty, it will secure continuous supply revenue from exclusive consumables, establishing a recurring revenue-based business structure.


HIC is a public research institute affiliated with the Vietnam Atomic Energy Institute (VINATOM) under the Ministry of Science and Technology of Vietnam, with research and production capabilities in radioisotopes and radiopharmaceuticals. In Vietnam, HIC is the only organization equipped with facilities that meet manufacturing and quality control standards, enabling it to sell FDG externally. HIC will have the exclusive responsibility for manufacturing, distribution, and sales of ProstaView within Vietnam, while FutureChem will support HIC with documentation related to manufacturing technologies required for local product approval and production, as well as supply key ingredients and exclusive consumables.


This agreement marks FutureChem's third achievement in Asian market expansion, following the ProstaView supply and distribution agreement signed in May with TMI, a medical device distributor in Indonesia, and the exclusive supply agreement for Alzaview concluded this month with Shreeji Imaging and Diagnostic Centre, a radiopharmaceutical specialist in India. The company highlighted that the Vietnam deal goes beyond mere consumable supply, embodying an expanded cooperation model that covers exclusive licensing, technology transfer for manufacturing, local product approval, as well as production, distribution, and sales.



A FutureChem representative commented, "By establishing local production and supply bases for ProstaView in Vietnam immediately after Indonesia, we are accelerating our entry into the Southeast Asian market," adding, "Based on this agreement, we will work to ensure successful product approval and commercialization in Vietnam without delay."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing